Pharmacokinetics of Levetiracetam
- 1 August 2001
- Vol. 42 (s4), 24-27
- https://doi.org/10.1046/j.1528-1157.2001.0420s4024.x
Abstract
Major considerations in the acceptance and impact of new antiepileptic drugs include their pharmacokinetics and their potential for interaction with other drugs. The pharmacokinetics of levetiracetam, a newly approved add-on antiepileptic agent for partial-onset seizures in adults, has been evaluated in 27 phase I and II studies. Consistent findings in these studies include rapid and complete oral absorption, linear dose kinetics, a minimal degree of protein binding, and predominantly renal excretion. Because of the lack of hepatic metabolism and low protein binding, the risk of interaction with other drugs is considered low.Keywords
This publication has 3 references indexed in Scilit:
- Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteersEpilepsy Research, 2001
- Absence of Pharmacokinetic Drug Interaction of Levetiracetam with Phenytoin in Patients with Epilepsy Determined by New TechniqueThe Journal of Clinical Pharmacology, 2000
- Pharmacokinetic profile of levetiracetamPharmacology & Therapeutics, 2000